Adherence to umeclidinium/vilanterol versus inhaled corticosteroids/long-acting ß2-agonist in patients with chronic obstructive pulmonary disease in England
A. Czira (Brentford, Middlesex, United Kingdom), G. Requena (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), C. Castillo (Bollington, Cheshire, United Kingdom), J. Yeap (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), M. Duarte (Brentford, Middlesex, United Kingdom), K. Rothnie (Brentford, Middlesex, United Kingdom), A. Ismaila (Collegeville, PA, United States)
Source: International Congress 2022 – COPD clinical studies and exacerbations
Session: COPD clinical studies and exacerbations
Session type: Thematic Poster
Number: 3619
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Czira (Brentford, Middlesex, United Kingdom), G. Requena (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), C. Castillo (Bollington, Cheshire, United Kingdom), J. Yeap (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), M. Duarte (Brentford, Middlesex, United Kingdom), K. Rothnie (Brentford, Middlesex, United Kingdom), A. Ismaila (Collegeville, PA, United States). Adherence to umeclidinium/vilanterol versus inhaled corticosteroids/long-acting ß2-agonist in patients with chronic obstructive pulmonary disease in England. 3619
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|